These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8121441)

  • 21. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS; Mukhopadhyay S
    Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
    [No Abstract]   [Full Text] [Related]  

  • 22. Antiplatelet therapy for ischemic heart disease.
    Lange RA; Hillis LD
    N Engl J Med; 2004 Jan; 350(3):277-80. PubMed ID: 14724308
    [No Abstract]   [Full Text] [Related]  

  • 23. IIb/IIIa platelet inhibitors in the management of coronary artery disease.
    Talley JD
    J Ark Med Soc; 1996 Oct; 93(5):237-9. PubMed ID: 8908943
    [No Abstract]   [Full Text] [Related]  

  • 24. Optimal treatment of acute coronary syndromes--an evolving strategy.
    Boden WE; McKay RG
    N Engl J Med; 2001 Jun; 344(25):1939-42. PubMed ID: 11419433
    [No Abstract]   [Full Text] [Related]  

  • 25. [Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease].
    Neumann FJ; Gawaz M; Schömig A
    Dtsch Med Wochenschr; 1997 Oct; 122(40):1224-30. PubMed ID: 9378047
    [No Abstract]   [Full Text] [Related]  

  • 26. Stents are the CADILLAC of care. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications.
    SoRelle R
    Circulation; 2002 Apr; 105(14):e9094-5. PubMed ID: 11942340
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
    Saw J; Moliterno DJ
    Coron Artery Dis; 2003 Aug; 14(5):373-80. PubMed ID: 12878902
    [No Abstract]   [Full Text] [Related]  

  • 29. [Medical progress exemplified by improvements in the safety coronary angioplasty].
    Metzger JP
    Bull Acad Natl Med; 2012 Oct; 196(7):1361-7; discussion 1367-8. PubMed ID: 23815020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

  • 31. Administering abciximab. A new drug for preventing coronary restenosis.
    Strimike CL; Wojcik JM
    Nursing; 1997 Mar; 27(3):32aa-32dd, 32ff. PubMed ID: 9171622
    [No Abstract]   [Full Text] [Related]  

  • 32. Coronary artery stenting during acute myocardial infarction in patients treated with IIb/IIIa anti-platelet antibodies: early outcome results.
    Murdock DK; Hoffman MT; Logemann TN; Kaufman JS; Engelmeier RS
    Wis Med J; 1996 Dec; 95(12):867-71. PubMed ID: 8993226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving microvascular perfusion with platelet glycoprotein IIb/IIIa receptor inhibition.
    Dippel EJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():12E-16E; quiz 17E. PubMed ID: 12668858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular Healing Evaluated by Intravascular Ultrasound and Optical Coherence Tomography.
    Romaguera R; Teruel L; Gómez-Hospital JA
    Rev Esp Cardiol (Engl Ed); 2016 Mar; 69(3):322. PubMed ID: 26522875
    [No Abstract]   [Full Text] [Related]  

  • 35. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 38. Intracoronary administration of abciximab acutely increases flow through culprit vessels of patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Burzotta F; Romagnoli E; Trani C; Crea F
    Circulation; 2003 Nov; 108(19):e138; author reply e138. PubMed ID: 14610001
    [No Abstract]   [Full Text] [Related]  

  • 39. The use of abciximab during percutaneous coronary angioplasty reduces ischaemic events, but the cost is prohibitive.
    Mayosi BM; Latouf SE; Commerford PJ
    S Afr Med J; 1998 Feb; 88(2):130-1. PubMed ID: 9717492
    [No Abstract]   [Full Text] [Related]  

  • 40. Murmurs from the heart (or why the stethoscope is not an economic tool).
    Aristides M; Gliksman M
    Heart; 1998 Jan; 79(1):10-1. PubMed ID: 9518073
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.